Ask about this productRelated genes to: Arnt antibody
- Gene:
- ARNT NIH gene
- Name:
- aryl hydrocarbon receptor nuclear translocator
- Previous symbol:
- -
- Synonyms:
- HIF-1beta, bHLHe2
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1990-01-22
- Date modifiied:
- 2016-10-05
Related products to: Arnt antibody
Related articles to: Arnt antibody
- Redox imbalance and impaired detoxification pathways have been implicated in prostate carcinogenesis; however, the specific genetic variants that modulate these processes remain insufficiently characterized. We used a two-stage, pathway-focused design in which PRACTICAL consortium meta-GWAS summary statistics (79,148 cases and 61,106 controls) were used for initial gene-level prioritization, whereas formal variant-level effect estimation was based on FinnGen and UK Biobank summary statistics (19,209 cases and 288,847 controls). PRACTICAL was not included in the formal variant-level meta-analysis because the available data had already been aggregated across multiple contributing studies and were annotated on a different genome build, limiting uniform harmonization and comparability with the two individual biobank datasets. The analysis evaluated 258 variants across 30 genes and prioritized four non-coding candidates: rs3738483 in ARNT, rs4130304 in NFE2L2, rs974334 in GPX6, and rs9606173 in TXNRD2. Three variants met the initial p<0.01 screening threshold; rs9606173 was retained as a borderline candidate (p = 0.011) because it satisfied the remaining allele-frequency, False positive report probability, linkage disequilibrium, functional, pathway-relevance, and assay-feasibility criteria. In the replication cohort (n=560), rs9606173 in TXNRD2 showed nominal associations with prostate cancer (PCa) risk under dominant and overdominant models, although neither association remained significant after Bonferroni correction. Computational annotations and TCGA-PRAD expression analyses supported the biological plausibility of the prioritized genes and variants but did not establish allele-specific function or causality. Overall, this study provides a pathway-based framework for prioritizing biologically plausible PCa susceptibility candidates. These findings should nevertheless be considered exploratory and require replication in larger independent cohorts, together with direct functional validation of the prioritized variants and the redox-regulatory and detoxification pathways highlighted by the analysis. - Source: PubMed
Publication date: 2026/08/27
Álvarez-González BeatrizMorales-Álvarez Carmen MariaPorras-Quesada PatriciaChica-Redecillas LuciaCañadas-Garre MarisaHernández Antonio FÁlvarez-Cubero María JesúsMartínez-González Luis Javier - A composite based on humic acid (HA) and reduced graphene oxide (rGO) was synthesized to evaluate the effect of rGO on the structural, functional, thermal, and preliminary phenol adsorption properties of humic acid. The incorporation of rGO increased the carbon content from 47.34 to 55.61 wt.% and decreased the oxygen content from 48.31 to 40.79 wt.%. At the same time, the total content of carboxyl and phenolic hydroxyl groups increased from 5.00 to 5.47 mmol/g, indicating improved accessibility of oxygen-containing functional sites. FTIR spectroscopy confirmed the retention of the main functional groups of the initial components after composite formation. Thermogravimetric analysis showed enhanced thermal stability, with the residual mass at 1000 °C increasing from 59.21 to 70.03%. Electron microscopy revealed the formation of a developed wrinkled surface morphology. Preliminary phenol adsorption experiments showed that the HA-rGO composite exhibited higher adsorption capacity than the initial HA and rGO. This improvement was attributed to the combined contribution of oxygen-containing functional groups and the aromatic carbon structure of rGO, which may promote hydrogen bonding and π-π interactions with phenol molecules. - Source: PubMed
Publication date: 2026/08/07
Zhakina Alma KhassenovnaArnt Oxana VasilievnaVassilets Yevgeniy PetrovichZhakin Almat MaulenulyMuldakhmetov Zainulla - Successful embryo development transpires far before fertilization inside the meticulously regulated microenvironment of the ovarian follicle. Increasing data indicates that circadian regulatory systems influence several processes that define oocyte competence, including mitochondrial activity, oxidative balance, meiotic development, and cellular metabolism. Brain and muscle ARNT-like protein 1 (BMAL1), an essential transcription factor in circadian regulation, has garnered significant interest due to its crucial involvement in ovarian physiology and reproductive function. Dysregulated BMAL1 signaling has been linked to compromised folliculogenesis, diminished steroidogenesis, mitochondrial dysfunction, elevated oxidative stress, and irregularities in meiotic spindle organization, all of which may negatively impact oocyte quality and early embryo development. Recent experimental and clinical findings indicate that results of assisted reproduction may be influenced by circadian disruption, sleep problems, obesity, ageing, and metabolic dysfunction. - Source: PubMed
Publication date: 2026/08/21
Voros CharalamposZagorianakou NektariaMakrydimas StylianosChatzinikolaou FotiosPapadimas GeorgiosKoulakmanidis Aristotelis MariosThomakos NikolaosAntsaklis PanagiotisDaskalakis GeorgiosMakrydimas George - While circadian disturbances are commonly comorbid with schizophrenia (SCZ), whether deficits in clock genes can induce SCZ-like behaviors in mice remains poorly understood. Brain and muscle Arnt-like protein 1 (Bmal1, also known as Mop3 or Arntl), a core circadian clock gene, is implicated in the regulation of circadian rhythms, and its single nucleotide polymorphism rs1982350 has been linked to the pathogenesis of SCZ. - Source: PubMed
Yao Yi-QinGuo Bo-WeiXu Zhi-YiWang CunHong HaoChen Zhi-GangTang Su-Su - In breast cancer (BC), neoadjuvant chemotherapy (NAC) improves surgical options, and pathologic complete response (pCR) predicts better outcomes. Patients with residual disease (non-pCR) have higher recurrence risk, yet robust pretreatment biomarkers remain limited. - Source: PubMed
Publication date: 2026/08/06
Li QiangChen JinhaoYu WeiLi XunDeng Yuhua